Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLB-01-007 long-term open-label extension of BBP-418 (ribitol) in LGMD2I/R9
2025-524371-23-00Phase 3Authorised
- Sponsor
- ML Bio Solutions
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of ribitol in limb-girdle muscular dystrophy type 2I (LGMD2I) and limb-girdle muscular dystrophy (LGMD), sponsored by ML Bio Solutions. Planned start Jun 2026; status: authorised.
02
Drugs
ribitol
03
Conditions
limb-girdle muscular dystrophy type 2I (LGMD2I)limb-girdle muscular dystrophy (LGMD)
Beyond the preview
Go deeper on 2025-524371-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524371-23-00.